JCR Pharmaceuticals
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
JCR Pharmaceuticals - overview
Established
1975
Location
-, -, Japan
Primary Industry
Pharmaceuticals
About
JCR Pharmaceuticals is a biopharmaceutical company focused on developing innovative therapies for rare diseases, particularly lysosomal storage disorders, with an emphasis on enzyme replacement therapies. Founded in 1975 in Japan, JCR Pharmaceuticals specializes in biopharmaceuticals. The company went public in April 2011. Under the leadership of CEO Vanessa Tubel, JCR Pharmaceuticals has maintained a steady focus on developing treatments for rare diseases.
JCR Pharmaceuticals develops and commercializes biopharmaceuticals aimed at treating lysosomal storage disorders. Its primary offerings include enzyme replacement therapies, which are designed to replace deficient enzymes, improving the quality of life for patients. The company caters to healthcare providers, hospitals, and specialty pharmacies in Japan, Europe, and North America, continually investing in R&D to enhance its product range. In the year 2023, JCR Pharmaceuticals reported a revenue of USD 254.
17 mn and an EBITDA of USD 51. 60 mn. The revenue is generated through direct sales of biopharmaceutical products and collaborations with larger pharmaceutical companies for distribution. JCR Pharmaceuticals is focused on expanding its product line and market presence.
The company plans to introduce new products targeting rare diseases and aims to enter additional markets in Europe and North America by 2025. The recent public offering in April 2011 has positioned the company to leverage capital towards these growth initiatives.
Current Investors
TPG Biotech
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceuticals
Website
www.jcrpharm.co.jp
Company Stage
Mature
Total Amount Raised
Subscriber access only
JCR Pharmaceuticals - financials
| Fiscal Year Ended | Mar 31, 2012 | Mar 31, 2013 | Mar 31, 2014 | Mar 31, 2015 | Mar 31, 2016 | Mar 31, 2017 | Mar 31, 2018 | Mar 31, 2019 | Mar 31, 2020 | Mar 31, 2021 | Mar 31, 2022 | Mar 31, 2023 | Mar 31, 2024 | Mar 31, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 12,845,064,000 | 14,099,910,000 | 15,705,912,000 | 16,855,654,000 | 17,438,377,000 | 18,085,035,000 | 20,594,000,000 | 23,160,000,000 | 24,781,000,000 | 30,085,000,000 | 51,082,000,000 | - | - | - |
| % Revenue Growth (YoY) | - | 9.8% | 11.4% | 7.3% | 3.5% | 3.7% | 13.9% | 12.5% | 7.0% | 21.4% | 69.8% | - | - | - |
| EBITDA (USD) | 2,191,187,000 | 2,130,105,000 | 2,657,462,000 | 3,366,988,000 | 3,560,425,000 | 3,809,541,000 | 5,166,000,000 | 6,310,000,000 | 4,678,000,000 | 10,161,000,000 | 21,938,000,000 | - | - | - |
| Operating Income (USD) | 1,089,765,000 | 1,150,920,000 | 1,545,468,000 | 2,014,600,000 | 2,152,770,000 | 2,362,003,000 | 3,784,000,000 | 4,967,000,000 | 3,244,000,000 | 8,269,000,000 | 19,993,000,000 | - | - | - |
| Operating Margin | 8.5% | 8.2% | 9.8% | 12.0% | 12.3% | 13.1% | 18.4% | 21.4% | 13.1% | 27.5% | 39.1% | - | - | - |
| % EBITDA Margin | 17.1% | 15.1% | 16.9% | 20.0% | 20.4% | 21.1% | 25.1% | 27.2% | 18.9% | 33.8% | 42.9% | - | - | - |
| NET Income (USD) | 634,011,000 | 730,837,000 | 1,296,332,000 | 1,682,418,000 | 1,789,597,000 | 1,863,270,000 | 3,069,000,000 | 3,710,000,000 | 2,679,000,000 | 6,888,000,000 | 14,517,000,000 | - | - | - |
| % Net Margin | 4.9% | 5.2% | 8.3% | 10.0% | 10.3% | 10.3% | 14.9% | 16.0% | 10.8% | 22.9% | 28.4% | - | - | - |
JCR Pharmaceuticals - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| IPO | Completed | JCR Pharmaceuticals | - | ||||||||
| Growth | Completed | JCR Pharmaceuticals | - |
Displaying 1 - 2 of 2
JCR Pharmaceuticals - key contacts
| Name | Position | Start Date | End Date | Vcard | Bio | ||
|---|---|---|---|---|---|---|---|
| Board Member | BM |
BM Board Member
Want to see more?
Request a demo for full access to this profile
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.